CASI Pharmaceuticals Divests Chinese Assets in $20 Million Deal

CASI Pharmaceuticals ( (CASI) ) has issued an announcement.

On May 12, 2025, CASI Pharmaceuticals announced a definitive agreement to divest its assets in China to Kaixin Pharmaceuticals for $20 million, including the assumption of up to $20 million in debt. This transaction, approved by CASI’s board and a special committee, involves transferring equity interests and rights related to specific pharmaceutical products. Post-transaction, CASI will focus on developing CID-103 for organ transplant rejection and autoimmune diseases, retaining rights to other key products.

The most recent analyst rating on (CASI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.

Spark’s Take on CASI Stock

According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.

CASI Pharmaceuticals faces substantial financial difficulties, with declining revenues and increasing losses, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and lack of dividends. These factors contribute to a low overall stock score, highlighting the need for significant improvements in operational efficiency and revenue growth.

To see Spark’s full report on CASI stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and globally. The company specializes in hematology oncology therapeutics and treatments for organ transplant rejection and autoimmune diseases, leveraging its China-based regulatory and commercial competencies and global drug development expertise.

Average Trading Volume: 9,569

Technical Sentiment Signal: Sell

Current Market Cap: $29.21M

See more data about CASI stock on TipRanks’ Stock Analysis page.